Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Bioxcel Therapeutics Inc (BTAI)

Bioxcel Therapeutics Inc (BTAI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 94,810
  • Shares Outstanding, K 37,035
  • Annual Sales, $ 1,380 K
  • Annual Income, $ -179,050 K
  • 60-Month Beta 0.43
  • Price/Sales 68.17
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade BTAI with:

Options Overview Details

View History
  • Implied Volatility 103.87% ( -10.07%)
  • Historical Volatility 55.23%
  • IV Percentile 23%
  • IV Rank 15.23%
  • IV High 382.30% on 04/22/24
  • IV Low 53.84% on 03/14/24
  • Put/Call Vol Ratio 5.60
  • Today's Volume 66
  • Volume Avg (30-Day) 171
  • Put/Call OI Ratio 0.44
  • Today's Open Interest 9,792
  • Open Int (30-Day) 9,229

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.68
  • Number of Estimates 2
  • High Estimate -0.67
  • Low Estimate -0.69
  • Prior Year -1.84
  • Growth Rate Est. (year over year) +63.04%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.50 +2.40%
on 05/02/24
3.10 -17.39%
on 04/12/24
-0.08 (-3.03%)
since 04/02/24
3-Month
1.91 +34.03%
on 02/09/24
4.17 -38.61%
on 02/06/24
-0.50 (-16.34%)
since 02/02/24
52-Week
1.91 +34.03%
on 02/09/24
29.56 -91.34%
on 05/10/23
-18.23 (-87.69%)
since 05/02/23

Most Recent Stories

More News
Anal Cancer Treatment Market Expected to Reach $1.63 Billion by 2030 as Latest Clinical Studies Focus on New Therapies

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:EXEL),(NYSE:PFE),(NASDAQ:BTAI),(NYSE:BMY) EQNX::TICKER_END

ONCY : 1.1700 (+4.46%)
ONC.TO : 1.59 (+3.25%)
EXEL : 22.12 (+0.89%)
PFE : 27.70 (+1.91%)
BTAI : 2.56 (+0.79%)
BMY : 43.70 (-1.15%)
Anal Cancer Treatment Market Expected to Reach $1.63 Billion by 2030 as Latest Clinical Studies Focus on New Therapies

ONCY : 1.1700 (+4.46%)
ONC.TO : 1.59 (+3.25%)
EXEL : 22.12 (+0.89%)
PFE : 27.70 (+1.91%)
BTAI : 2.56 (+0.79%)
BMY : 43.70 (-1.15%)
Unlocking AI investment opportunities in healthcare

AI is revolutionizing healthcare by improving diagnosis and accelerating drug discovery. An often-overlooked sector with a wealth of AI opportunities.

INTC : 30.51 (+0.46%)
NVDA : 858.17 (+3.34%)
RXRX : 8.79 (+5.40%)
RLAY : 7.08 (+6.31%)
EXAI : 5.09 (-0.97%)
RENB : 1.4900 (+1.36%)
BTAI : 2.56 (+0.79%)
Why Shares of BioXcel Therapeutics Fell This Week

The company's co-founder is leaving, and layoffs are coming.

BTAI : 2.56 (+0.79%)
Important September 5, 2023 Deadline Reminder: Kessler Topaz Meltzer & Check, LLP Reminds BioXcel Therapeutics, Inc. Investors of Securities Fraud Class Action Lawsuit

/PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in...

BTAI : 2.56 (+0.79%)
BTAI DEADLINE: ROSEN, NATIONAL INVESTOR COUNSEL, Encourages BioXcel Therapeutics, Inc. Investors With Losses to Secure Counsel Before Important September 5 Deadline in Securities Class Action - BTAI

/PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of BioXcel Therapeutics, Inc. (NASDAQ: BTAI) between...

BTAI : 2.56 (+0.79%)
BIOXCEL DEADLINE ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In BioXcel To Contact Him Directly To Discuss Their Options

/PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against BioXcel Therapeutics, Inc. ("BioXcel"...

BTAI : 2.56 (+0.79%)
SHAREHOLDER ALERT: Levi & Korsinsky Notifies BioXcel Therapeutics, Inc.(BTAI) Investors of a Class Action Lawsuit and Upcoming Deadline

/PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in BioXcel Therapeutics, Inc. ("BioXcel" or the "Company") (NASDAQ: BTAI) of a class action securities...

BTAI : 2.56 (+0.79%)
BTAI Investors Have Opportunity to Lead BioXcel Therapeutics, Inc. Securities Fraud Lawsuit

/PRNewswire/ -- Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action...

BTAI : 2.56 (+0.79%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of BioXcel Therapeutics, Inc. - BTAI

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of BioXcel Therapeutics, Inc. ("BioXcel" or the "Company") (NASDAQ: BTAI). Such...

BTAI : 2.56 (+0.79%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

BioXcel Therapeutics Inc. is a clinical stage biopharmaceutical company. It focuses on drug development which utilizes novel artificial intelligence to identify the next wave of medicines across neuroscience and immuno-oncology. The company's product portfolio include BXCL501, a sublingual thin film...

See More

Key Turning Points

3rd Resistance Point 2.67
2nd Resistance Point 2.63
1st Resistance Point 2.59
Last Price 2.56
1st Support Level 2.51
2nd Support Level 2.47
3rd Support Level 2.43

See More

52-Week High 29.56
Fibonacci 61.8% 19.00
Fibonacci 50% 15.73
Fibonacci 38.2% 12.47
Last Price 2.56
52-Week Low 1.91

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar